AGAP2 and neoplasm: Gliomas have also been targeted for MSC-exo therapy, with the overexpression of miR-199a having a profound effect on tumor sensitivity to temozolomide with inhibition of tumor growth, likely due to a downregulation of ADP-ribosylation factor GTPase-activating proteins with a GTPase domain, ankyrin repeat, and PH domain 2 (AGAP2) [150].